- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05283720
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination With Anti-Neoplastic Agents in Subjects With Non-Hodgkin Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed.
Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 394 adult participants with NHL will be enrolled in 100 sites globally.
In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28-day or 21 day cycles dependent on the arm in combination with the anti-neoplastic agents described below:
1: Oral lenalidomide in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in participants with with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in participants with newly diagnosed treatment-naïve DLBCL; 4: Oral CC-99282 in participants with R/R DLBCL; 5: Oral CC-99282 in participants with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in participants with R/R mantle cell lymphoma (MCL); 6B: Oral ibrutinib, and oral venetoclax in participants with R/R MCL; 7: Oral ibrutinib, and oral venetoclax in participants with newly diagnosed treatment-naïve MCL.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: ABBVIE CALL CENTER
- Phone Number: 844-663-3742
- Email: abbvieclinicaltrials@abbvie.com
Study Locations
-
-
-
Brno, Czechia, 613 00
- Recruiting
- Fakultni nemocnice Brno /ID# 242683
-
Hradec Kralove, Czechia, 500 05
- Recruiting
- Fakultni nemocnice Hradec Kralove /ID# 241722
-
Ostrava, Czechia, 708 52
- Recruiting
- Fakultni Nemocnice Ostrava /ID# 242684
-
Praha, Czechia, 128 08
- Recruiting
- Vseobecna fakultni nemocnice v Praze /ID# 242685
-
-
-
-
Midtjylland
-
Aarhus, Midtjylland, Denmark, 8200
- Recruiting
- Aarhus Universitetshospital - Skejby /ID# 242670
-
-
Nordjylland
-
Aalborg, Nordjylland, Denmark, 9000
- Recruiting
- Aalborg University Hospital /ID# 242734
-
-
-
-
-
Créteil, France, 94010
- Recruiting
- Hôpitaux Universitaires Henri Mondor - Hôpital Henri Mondor /ID# 242337
-
Paris, France, 75013
- Recruiting
- Hopital Pitie Salpetriere /ID# 242343
-
Toulouse Cedex 9, France, 31059
- Recruiting
- IUCT Oncopole /ID# 242340
-
-
Auvergne-Rhone-Alpes
-
Clermont, Auvergne-Rhone-Alpes, France, 63100
- Recruiting
- CHU Clermont-Ferrand /ID# 242344
-
-
Bretagne
-
Rennes, Bretagne, France, 35000
- Recruiting
- CHU de Rennes - PONTCHAILLOU /ID# 242339
-
-
Ile-de-France
-
Paris, Ile-de-France, France, 75010
- Recruiting
- Institut de Recherche Saint Louis - Hopital St Louis /ID# 242336
-
-
Meurthe-et-Moselle
-
Vandoeuvre-les-Nancy, Meurthe-et-Moselle, France, 54500
- Recruiting
- CHRU Nancy - Hopitaux de Brabois /ID# 242342
-
-
Nord
-
Lille, Nord, France, 59037
- Recruiting
- CHRU Lille - Hopital Claude Huriez /ID# 242335
-
-
Pays-de-la-Loire
-
Nantes, Pays-de-la-Loire, France, 44000
- Recruiting
- CHU de Nantes, Hotel Dieu -HME /ID# 242345
-
-
Rhone
-
Pierre Benite CEDEX, Rhone, France, 69495
- Recruiting
- HCL - Hopital Lyon Sud /ID# 242349
-
-
-
-
-
Marburg, Germany, 35043
- Recruiting
- Universitaetsklinikum Giessen und Marburg /ID# 245308
-
Regensburg, Germany, 93042
- Recruiting
- Universitaetsklinikum Regensburg /ID# 244517
-
Wuerzburg, Germany, 97080
- Recruiting
- Universitaetsklinikum Wuerzburg /ID# 245453
-
-
Baden-Wuerttemberg
-
Ulm, Baden-Wuerttemberg, Germany, 89081
- Recruiting
- Universitaetsklinikum Ulm /ID# 244265
-
-
Sachsen
-
Leipzig, Sachsen, Germany, 04103
- Recruiting
- Universitaetsklinikum Leipzig /ID# 245513
-
-
-
-
-
Budapest, Hungary, 1085
- Recruiting
- Semmelweis Egyetem /ID# 242454
-
Budapest, Hungary, 1122
- Recruiting
- Orszagos Onkologiai Intezet /ID# 242458
-
-
Hajdu-Bihar
-
Debrecen, Hajdu-Bihar, Hungary, 4032
- Recruiting
- Debreceni Egyetem-Klinikai Kozpont /ID# 242450
-
-
Somogy
-
Kaposvár, Somogy, Hungary, 7400
- Recruiting
- Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 245935
-
-
-
-
H_efa
-
Haifa, H_efa, Israel, 4941492
- Recruiting
- Rabin Medical Center /ID# 243014
-
-
Tel-Aviv
-
Ramat Gan, Tel-Aviv, Israel, 5265601
- Recruiting
- The Chaim Sheba Medical Center /ID# 243010
-
Tel Aviv, Tel-Aviv, Israel, 6423906
- Recruiting
- Tel Aviv Sourasky Medical Center /ID# 243012
-
-
Yerushalayim
-
Jerusalem, Yerushalayim, Israel, 91120
- Recruiting
- Hadassah Medical Center-Hebrew University /ID# 243013
-
-
-
-
Hokkaido
-
Sapporo-shi, Hokkaido, Japan, 060-8648
- Recruiting
- Hokkaido University Hospital /ID# 248999
-
-
Kyoto
-
Kyoto-shi, Kyoto, Japan, 606-8507
- Recruiting
- Kyoto University Hospital /ID# 248997
-
-
Tokyo
-
Chuo-ku, Tokyo, Japan, 104-0045
- Recruiting
- National Cancer Center Hospital /ID# 248995
-
-
-
-
-
Seoul, Korea, Republic of, 03080
- Recruiting
- Seoul National University Hospital /ID# 242402
-
Seoul, Korea, Republic of, 06351
- Recruiting
- Samsung Medical Center /ID# 242401
-
-
Gyeonggido
-
Seongnam-si, Gyeonggido, Korea, Republic of, 13620
- Recruiting
- Seoul National University Bundang Hospital /ID# 242404
-
-
Seoul Teugbyeolsi
-
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 05505
- Recruiting
- Asan Medical Center /ID# 242400
-
Seoul, Seoul Teugbyeolsi, Korea, Republic of, 06591
- Recruiting
- The Catholic University of Korea, Seoul St. Marys Hospital /ID# 242403
-
-
-
-
-
Amsterdam, Netherlands, 1081 HV
- Recruiting
- Vrije Universiteit Medisch Centrum /ID# 243319
-
Groningen, Netherlands, 9713 GZ
- Recruiting
- Universitair Medisch Centrum Groningen /ID# 243318
-
Leiden, Netherlands, 2333 ZA
- Recruiting
- Leids Universitair Medisch Centrum /ID# 243316
-
Maastricht, Netherlands, 6229 HX
- Recruiting
- Maastricht Universitair Medisch Centrum /ID# 243317
-
-
Zuid-Holland
-
Rotterdam, Zuid-Holland, Netherlands, 3015 GD
- Completed
- Duplicate_Erasmus Medisch Centrum /ID# 243315
-
-
-
-
-
Barcelona, Spain, 08035
- Recruiting
- Hospital Universitario Vall d'Hebron /ID# 243260
-
Madrid, Spain, 28027
- Recruiting
- CLINICA UNIVERSIDAD DE NAVARRA-Madrid /ID# 243268
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre /ID# 243262
-
Madrid, Spain, 28040
- Recruiting
- Hospital Universitario Fundacion Jimenez Diaz /ID# 243264
-
Salamanca, Spain, 37711
- Recruiting
- Hospital Universitario de Salamanca /ID# 243368
-
Sevilla, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocio /ID# 243267
-
Valencia, Spain, 46010
- Recruiting
- Hospital Clinico Universitario de Valencia /ID# 243269
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- Instituto Catalan de Oncologia (ICO) Badalona /ID# 243265
-
Hospitalet de Llobregat, Barcelona, Spain, 08908
- Recruiting
- Instituto Catalan de Oncologia (ICO) L'Hospitalet /ID# 243261
-
-
Navarra
-
Pamplona, Navarra, Spain, 31008
- Recruiting
- Clinica Universidad de Navarra - Pamplona /ID# 245031
-
-
-
-
-
Taichung, Taiwan, 40447
- Recruiting
- China Medical University Hospital /ID# 242893
-
Tainan, Taiwan, 704
- Recruiting
- National Cheng Kung University Hospital /ID# 242894
-
Taipei, Taiwan, 11217
- Recruiting
- Taipei Veterans General Hosp /ID# 242892
-
-
-
-
Arizona
-
Tucson, Arizona, United States, 85719-1478
- Recruiting
- University of Arizona Cancer Center - North Campus /ID# 242219
-
-
Connecticut
-
New Haven, Connecticut, United States, 06510
- Recruiting
- Yale University /ID# 242089
-
-
Delaware
-
Newark, Delaware, United States, 19713
- Recruiting
- Christiana Care Health Service /ID# 242301
-
-
Florida
-
Tampa, Florida, United States, 33606
- Recruiting
- Tampa General Hospital /ID# 246748
-
-
Georgia
-
Atlanta, Georgia, United States, 30322-1013
- Recruiting
- Emory University /ID# 242153
-
-
Maryland
-
Baltimore, Maryland, United States, 21201-1544
- Recruiting
- University of Maryland School of Medicine /ID# 242218
-
-
Missouri
-
Kansas City, Missouri, United States, 64114-4859
- Recruiting
- Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144
-
-
New York
-
Lake Success, New York, United States, 11042
- Recruiting
- Northwell Health - Monter Cancer Center /ID# 245435
-
New York, New York, United States, 10029
- Recruiting
- Icahn School of Medicine at Mount Sinai /ID# 242123
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Recruiting
- Novant Health Presbyterian Medical Center /ID# 242148
-
Greenville, North Carolina, United States, 27834
- Recruiting
- East Carolina University Brody School of Medicine /ID# 242506
-
Winston-Salem, North Carolina, United States, 27103
- Recruiting
- Novant Health Forsyth Medical Center /ID# 242198
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19107-4414
- Recruiting
- Thomas Jefferson University /ID# 242077
-
Philadelphia, Pennsylvania, United States, 19111
- Completed
- Fox Chase Cancer Center /ID# 242106
-
-
Tennessee
-
Knoxville, Tennessee, United States, 37916
- Recruiting
- Thompson Cancer Survival Ctr /ID# 242150
-
-
Texas
-
Lubbock, Texas, United States, 79410
- Recruiting
- Joe Arrington Cancer Research /ID# 242226
-
-
Washington
-
Seattle, Washington, United States, 98104
- Recruiting
- Swedish Cancer Institute- First Hill /ID# 242269
-
Tacoma, Washington, United States, 98405
- Recruiting
- Multicare Institute for Research and Innovation /ID# 242127
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Diagnosis of:
-- Diffuse large B-cell lymphoma (DLBCL) (de novo or histologically transformed from follicular lymphoma (FL) or nodal marginal zone lymphoma) with histologically confirmed CD20+ disease, inclusive of the following according to World Health Organization (WHO) 2016 classification and documented in pathology report:
- DLBCL, not otherwise specified (NOS).
- High-grade B cell lymphoma with MYC and BCL-2 and/or BCL-6 translocations per WHO 2016 ("double-hit" or "triple-hit") Note: High-grade B-cell lymphomas NOS or other double- /triple-hit lymphomas (with histologies not consistent with DLBCL) are not eligible.
- Follicular lymphoma (FL) Grade 3B. OR
- FL with histologically confirmed CD20+ Grade 1 to 3a and no evidence of histologic transformation to an aggressive lymphoma at most recent representative tumor biopsy, according to WHO 2016 classification. OR
- Mantle cell lymphoma (MCL) with histologically confirmed CD20+ disease at most recent representative tumor biopsy according to the WHO 2016 classification with evidence of overexpression of cyclin D1 in association with relevant markers or evidence of t(11;14) assessed by flow cytometry, FISH, or polymerase chain reaction (PCR).
- Eastern Cooperative Oncology Group (ECOG) performance status 0 - 2, except for Arms 6 and 7 where ECOG performance status must be 0-1.
Must have 1 or more measurable disease sites:
- A positron emission tomography (PET) /computed tomography (CT) scan demonstrating PET-positive lesion(s) AND
- At least 1 measurable nodal lesion (long axis > 1.5 cm) or >= 1 measurable extra-nodal lesion (long axis > 1.0 cm) on CT scan or magnetic resonance imaging (MRI).
Exclusion Criteria:
- Prior treatment with epcoritamab or any other bispecific antibody targeting CD3 and CD20.
- Toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Events (CTCAE, v 5.0), Grade 2 or below, with the exception of alopecia. Other eligibility criteria (e.g., laboratory, cardiac criteria) must also be met.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1: Dose Escalation
Participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) will receive escalating doses of subcutaneous (SC) epcoritamab in combination with oral lenalidomide in 28 day cycles.
|
Oral; Capsule
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Arm 2: Dose Escalation
Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
|
Oral; Capsule
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
Other Names:
|
Experimental: Arm 3: Dose Escalation
Participants with newly diagnosed treatment-naïve DLBCL will receive escalating doses of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Intravenous (IV); Injection
IV; Injection
IV; Injection
Oral; Tablet
IV; Injection
|
Experimental: Arm 1: Dose Expansion
Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral lenalidomide in 28 day cycles.
|
Oral; Capsule
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Arm 2: Dose Expansion
Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib and oral lenalidomide in 28 day cycles.
|
Oral; Capsule
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
Other Names:
|
Experimental: Arm 3: Dose Expansion
Participants newly diagnosed treatment-naïve DLBCL will receive the recommended dose of SC epcoritamab in combination with intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in 21 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Intravenous (IV); Injection
IV; Injection
IV; Injection
Oral; Tablet
IV; Injection
|
Experimental: Arm 4: Dose Escalation
Participants with R/R DLBCL will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
|
Experimental: Arm 5: Dose Escalation
Participants with R/R follicular lymphoma (FL) will receive escalating doses of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
|
Experimental: Arm 6A: Dose Escalation
Participants with R/R mantle cell lymphoma (MCL) will receive escalating doses of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
Other Names:
|
Experimental: Arm 6B: Dose Escalation
Participants with R/R MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
Other Names:
Oral; Tablet
Other Names:
|
Experimental: Arm 7: Dose Escalation
Participants with newly diagnosed treatment-naïve MCL will receive escalating doses of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Arm 4: Dose Expansion
Participants with R/R DLBCL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Arm 5: Dose Expansion
Participants with R/R FL will receive the recommended dose of SC epcoritamab in combination with oral CC-99282 in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
|
Experimental: Arm 6: Dose Expansion
Participants with R/R MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib in 28 day cycles.
|
Subcutaneous Injection (SC)
Other Names:
Oral; Capsule
Other Names:
|
Experimental: Arm 7: Dose Expansion
Participants with newly diagnosed treatment-naïve MCL will receive the recommended dose of SC epcoritamab in combination with oral ibrutinib, and oral venetoclax in 28 day cycles.
|
Oral; Capsule
Other Names:
Oral; Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Dose-Limiting Toxicities (DLT)
Time Frame: Up to Approximately 5 Years
|
DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
|
Up to Approximately 5 Years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of response (DOR) per Investigator
Time Frame: Up to Approximately 5 Years
|
DOR is defined for participants who achieved best overall response of CR or PR ('responders'), as the time in months from initial CR/PR to the earliest occurrence of radiographic progression determined by Lugano 2014 criteria as assessed by the investigator, or death from any cause.
|
Up to Approximately 5 Years
|
Number of Participants with Progression-free survival (PFS)
Time Frame: Up to Approximately 5 Years
|
PFS is defined as the time in months from the first dose of study drug to the earliest occurrence of disease progression determined by Lugano 2014 criteria as assessed by investigator, or death from any cause.
|
Up to Approximately 5 Years
|
Percentage of Participants with Complete Response (CR)
Time Frame: Up to Approximately 5 Years
|
CR is defined as the percentage of participantswho achieved best overall response of CR determined by Lugano 2014 criteria as assessed by investigator.
|
Up to Approximately 5 Years
|
Time-to-response (TTR)
Time Frame: Up to Approximately 5 Years
|
TTR is defined as the number of months from the date of first dose to the date of best overall response of CR or PR ('responders') determined by Lugano 2014 criteria as assessed by investigator.
|
Up to Approximately 5 Years
|
Rate of Minimal Residual Disease (MRD) Negativity
Time Frame: Up to Approximately 5 Years
|
MRD is defined as the percentage of participants with assessment of the minimal residual disease.
|
Up to Approximately 5 Years
|
Overall Survival (OS)
Time Frame: Up to Approximately 5 Years
|
(OS) is defined as the time in months from first dose of epcoritamab to death from any cause.
|
Up to Approximately 5 Years
|
Best Overall Response (BOR) per Investigator
Time Frame: Up to Approximately 5 Years
|
BOR is defined as the percentage of participants who achieved best overall response of CR or PR by Lugano 2014 criteria as assessed by the investigator.
|
Up to Approximately 5 Years
|
Time to Next Antilymphoma Therapy (TTNT)
Time Frame: Up to Approximately 5 Years
|
Time to next antilymphoma therapy.
|
Up to Approximately 5 Years
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Cancer
- Rituximab
- Lenalidomide
- Cyclophosphamide
- Ibrutinib
- Non-Hodgkin Lymphoma
- ABT-199
- Venclexta
- GDC-0199
- Epcoritamab
- ABBV-GMAB-3013
- Doxorubicin Hydrochloride (HCl]
- Prednisone (pola-R-CHP)
- Polatuzumab Vedotin
- CC-99282
- Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Venetoclax,
- EPCORE
Additional Relevant MeSH Terms
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma
- Lymphoma, Non-Hodgkin
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Antibiotics, Antineoplastic
- Immunoconjugates
- Tyrosine Kinase Inhibitors
- Cyclophosphamide
- Lenalidomide
- Venetoclax
- Rituximab
- Prednisone
- Doxorubicin
- Liposomal doxorubicin
- Polatuzumab vedotin
- Ibrutinib
Other Study ID Numbers
- M22-132
- 2021-005725-24 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non-Hodgkin Lymphoma
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin LymphomaUnited States
-
Marker Therapeutics, Inc.RecruitingNon Hodgkin Lymphoma | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, RelapsedUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)CompletedRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Mantle Cell Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
National Cancer Institute (NCI)RecruitingRefractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Transformed Non-Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent T-Cell Non-Hodgkin Lymphoma | Recurrent Primary Cutaneous... and other conditionsUnited States
-
Caribou Biosciences, Inc.RecruitingLymphoma | Lymphoma, Non-Hodgkin | B Cell Lymphoma | Non Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | B Cell Non-Hodgkin's LymphomaUnited States, Australia, Israel
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingRefractory Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory T-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation RecipientUnited States
-
University of WashingtonRecruitingRecurrent Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin LymphomaUnited States
-
Chongqing Precision Biotech Co., LtdRecruitingNon Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Relapsed Non-Hodgkin LymphomaChina
-
Estrella Biopharma, Inc.Eureka Therapeutics Inc.Not yet recruitingLymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
-
Acerta Pharma BVAstraZenecaActive, not recruitingNon Hodgkin LymphomaUnited States, Canada, Italy
Clinical Trials on Lenalidomide
-
Sidney Kimmel Comprehensive Cancer Center at Johns...TerminatedMyelodysplastic SyndromeUnited States
-
Grupo Español de Linfomas y Transplante Autólogo...Celgene Corporation; Dynamic Science S.L.; Thermo Fisher Scientific, IncCompleted
-
Celgene CorporationICON Clinical ResearchCompletedMyelodysplastic SyndromesGermany, Israel, United Kingdom, Spain, Belgium, Italy, France, Netherlands, Sweden
-
Swiss Group for Clinical Cancer ResearchTerminatedLymphomaSwitzerland, Norway, Sweden
-
Boston VA Research Institute, Inc.Celgene Corporation; Edward Hines Jr. VA Hospital; Michael E. DeBakey VA Medical... and other collaboratorsCompletedMultiple MyelomaUnited States
-
Dana-Farber Cancer InstituteBeth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital and other collaboratorsTerminatedWaldenstrom's MacroglobulinemiaUnited States
-
University Hospital, ToulouseCelgene Corporation; Janssen-Cilag Ltd.Completed
-
CelgeneCompletedRelapsed or Refractory Chronic Lymphocytic LeukemiaUnited States, Canada, United Kingdom, France, Germany, Spain, Italy, Sweden
-
Groupe Francophone des MyelodysplasiesUnknownMyelodysplastic SyndromesFrance